XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements Of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows provided by (used in) operating activities:      
Net loss of ZimVie Inc. $ (393,282) $ (63,881) $ (95,254)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation and amortization 121,686 122,789 129,719
Share-based compensation 27,020 30,289 7,309
Deferred income tax provision (17,088) (70,422) (22,089)
Loss on disposal of fixed assets 2,996 3,358 0
Other non-cash items 3,245 1,172 0
Write-down of spine disposal group to fair value [2] 289,456 [1] 0 [1] 0
Changes in operating assets and liabilities, net of acquired assets and liabilities      
Income taxes (15,054) 5,485 (3,201)
Accounts receivable 21,083 (26,156) 27,172
Related party receivables 8,483 (8,483) 0
Inventories 25,446 10,210 33,062
Prepaid expenses and other current assets 5,340 (19,951) (673)
Accounts payable and accrued liabilities (24,759) 21,842 (6,591)
Related party payables (13,176) 13,176 0
Other assets and liabilities (4,248) 5,200 (5,169)
Net cash provided by operating activities 37,148 24,628 64,285
Cash flows used in investing activities:      
Additions to instruments (5,978) (10,089) (28,244)
Additions to other property, plant and equipment (6,509) (16,457) (28,405)
Other investing activities (2,687) (2,117) (3,700)
Net cash used in investing activities (15,174) (28,663) (60,349)
Cash flows provided by (used in) financing activities:      
Net transactions with Zimmer Biomet 0 6,920 90,006
Dividend paid to Zimmer Biomet 0 (540,567) 0
Proceeds from debt 4,760 595,000 0
Payments on debt (29,304) (58,544) 0
Debt issuance costs 0 (5,170) 0
Repayments of debt due to Zimmer Biomet 0 0 (16,905)
Payments related to tax withholding for share-based compensation (3,402) 0 0
Proceeds from stock option activity 2,280 1,059 0
Other financing activities 0 (5) (752)
Net cash (used in) provided by financing activities (25,666) (1,307) 72,349
Effect of exchange rates on cash and cash equivalents 1,859 (5,456) (3,305)
(Decrease) increase in cash and cash equivalents (1,833) (10,798) 72,980
Cash and cash equivalents, beginning of year 89,601 100,399 27,419
Cash and cash equivalents, end of period 87,768 89,601 100,399
Supplemental Cash Flow Information [Abstract]      
Income taxes paid, net 20,152 25,730 12,089
Interest Paid 37,709 17,283 0
Non-cash settlement of debt due to parent 0 0 4,939
Derecognition of right-of-use assets (1,222) (14,174) 0
Derecognition of lease liabilities $ 1,225 $ 15,303 $ 0
[1] This write-down is reflected in Noncurrent assets of discontinued operations in the consolidated balance sheets.
[2] We performed an impairment analysis of the spine segment in December 2023 on a held-for-sale basis. The fair value of consideration to be received upon closure of the transaction was less than the carrying value of the spine segment's net assets and the difference represents the amount of the write-down.